Integene is a privately held biotechnology company based in Miami, Florida, developing a platform gene therapy technology
capable of treating a broad base of vascular diseases, including
peripheral arterial disease (PAD), critical limb ischemia (CLI),
coronary artery disease (CAD) and other vascular disorders.
The Company has an experienced management team in place, whose
business strategy is to focus first on a single indication, end-stage critical limb ischemia, in which the company has been granted Orphan Drug designation by the US FDA and is in the process of seeking fast-track regulatory status.
We intend to advance this indication to a Phase I/II clinical efficacy and
safety study in 2016, then partner with a large pharmaceutical company upon the achievement of positive human clinical results (estimated in 2018) to advance to
late stage clinical development, regulatory approval, additional
indications and commercialization.